Lipitor, Atorvastatin
Lipitor, Atorvastatin Newswire (Page 9)

Lipitor, Atorvastatin Newswire (Page 9)

Comprehensive Real-Time News Feed for Lipitor, Atorvastatin (generic). (Page 9)

Results 161 - 180 of 1,084 in Lipitor, Atorvastatin (generic)

  1. Prepare for medicine price turmoilRead the original story w/Photo

    May 27, 2015 |

    AFTER sharing a meal with his family, Jeffrey Spector made the decision to end his life on Friday May 22, 2015. This is why.


  2. Amgen's Cholesterol Fighting Drug Receives EU ApprovalRead the original story

    May 26, 2015 |

    The biopharmaceutical company, Amgen Inc . , has been bringing several drugs into the U.S. market which have helped to improve its sales over the years.


  3. Fight over hot new cholesterol drugs may be won in milligramsRead the original story

    May 25, 2015 | WNFL-AM Green Bay

    Two powerful and innovative cholesterol drugs likely to be approved this summer both target the same protein and have been shown to sharply lower LDL in high-risk patients. But there is at least one significant difference between the two offerings: the dosages in which they will be sold.


  4. E.U. Panel Backs Amgen Cholesterol DrugRead the original story

    May 22, 2015 | Los Angeles Business Journal Online

    Amgen Inc. announced Friday that a European Union committee has recommended approval of its drug Repatha to treat high cholesterol. The Thousand Oaks biotech said the Committee for Medicinal Products for Human Use of the European Medicines Agency has "adopted a positive opinion" to allow marketing for patients who don't respond or have intolerance to other cholesterol drugs.


  5. Would Pfizer Buying GlaxoSmithKline Make Sense?Read the original story w/Photo

    May 22, 2015 | Investopedia

    The Pfizer conundrum What makes this outperformance so unique and strange is the fact that growth stocks are typically the most prominent outperformers during a bull market, while income plays and mature growth opportunities, such as Pfizer, often underperform the broad market. To make matters even more confusing, patent exclusivity losses have hit Pfizer hard.


  6. Abstract 280: Defining Statin Intolerance Among High Cardiovascular...Read the original story

    Apr 29, 2015 | Circulation

    Introduction: The clinical and economic impact of statin intolerance in high CV risk patients is unknown due, in part, to a lack of consensus in its definition. We sought to define and validate an SI algorithm for use in an administrative database among high-CV risk patients Methods: Adults with a94%) across all 3 algorithms.


  7. Cholesterol Drugs May Lower Stroke Risk for Healthy Older AdultsRead the original story w/Photo

    May 19, 2015 | WebMD

    Healthy older adults who take cholesterol -lowering drugs may be cutting their risk of stroke , a new French study suggests. The study found that when people took medications called statins or fibrates, their risk of stroke over almost a decade went down by about one-third.


  8. Patient and physician factors influence decision-making in...Read the original story

    May 19, 2015 | Lipids in Health and Disease

    Background Goal attainment of guideline-recommended low-density lipoprotein cholesterol is suboptimal. Little is known about how patient factors influence physicians' treatment decision-making in hypercholesterolemia.


  9. Cholesterol Drugs May Lower Stroke Risk for Healthy Older AdultsRead the original story w/Photo

    May 19, 2015 |

    Healthy older adults who take cholesterol-lowering drugs may be cutting their risk of stroke, a new French study suggests. The study found that when people took medications called statins or fibrates, their risk of stroke over almost a decade went down by about one-third.


  10. Progress of Federal Lipitor Lawsuits to Be Addressed During May Case Management ConferenceRead the original story w/Photo

    May 17, 2015 | PRWeb

    Bernstein Liebhard is representing federal Lipitor lawsuit plaintiffs, all of whom allegedly developed Type 2 diabetes due to their use of the cholesterol-lowering statin medication. Our Firm is representing Lipitor lawsuit plaintiffs in the federal multidistrict litigation, and the issues to be addressed at this month's conference will likely prove relevant to our clients.


  11. Lipitor Lawsuit News: Federal Court Issues New Order Allowing...Read the original story w/Photo

    May 15, 2015 | PRWeb

    Bernstein Liebhard LLP is representing plaintiffs in federal Lipitor lawsuits that accuse Pfizer, Inc. of failing to warn patients about the alleged association between Lipitor and Type 2 diabetes. Our Firm is representing clients in this proceeding, and this Order will allow plaintiffs to present information that may prove relevant to their claims.


  12. Best Russell 1000 Healthcare Stocks According To A Very Useful Ranking System: A Look At AmgenRead the original story w/Photo

    May 12, 2015 | Seeking Alpha

    Healthcare stocks have performed very well in the last few years. In fact, among the 96 Russell 1000 healthcare companies, 91 have shown a positive return in the last 52 weeks.


  13. "Indoco Remedies Limited (INDOCO) - Pharmaceuticals & Healthcare -...Read the original story

    May 12, 2015 |

    The company manufactures and markets formulations and active pharmaceutical ingredients. It offers products in the fields of anti-diabetics, cardiovascular, central nervous system, musculo-skeletal, nutrition and dental care.


  14. Pfizer buys stake in AM-Pharma; option to acquireRead the original story w/Photo

    May 11, 2015 | MarketWatch

    Pfizer Inc. has purchased a minority stake in Dutch biopharmaceutical company AM-Pharma, which is working on treatments for conditions including acute kidney injury, and has an exclusive option to buy the whole company. Pfizer made an upfront payment of $87.5 million.


  15. Therapeutic Substitution From Atorvastatin to Simvastatin: Impact on...Read the original story

    May 11, 2015 | The American Journal of Managed Care

    Therapeutic substitution of less expensive statin drugs has been used to control pharmacy costs, but questions remain about whether low-density lipoprotein cholesterol outcomes are equivalent. To evaluate the impact of LDL level differences between patients who did and did not switch from atorvastatin to equipotent doses of simvastatin through a therapeutic substitution program.


  16. Esperion Therapeutics' (ESPR) CEO Tim Mayleben on Q1 2015 Results - Earnings Call TranscriptRead the original story w/Photo

    May 7, 2015 | Seeking Alpha

    Good day, ladies and gentlemen and welcome to the Esperion Therapeutics First Quarter 2015 Conference Call. At this time all participants are in a listen-only mode.


  17. Pfizer's 3 Most Important NumbersRead the original story w/Photo

    May 8, 2015 | Investopedia

    Last year alone, it generated $15.3 billion in free cash flow on the heels of a gross margin figure that nearly hit 81%. But, just because Pfizer is a cash cow doesn't necessarily mean it's an automatic buy for short- or long-term investors.


  18. Budget to slash some drug pricesRead the original story w/Photo

    May 6, 2015 |

    HER blood was found in pipes and on knives in her parents home, now police have charged this four-year-old's father with a shocking crime. TONY Abbott says Joe Hockey won't be sacked if the Budget is a flop and that all ministers involved in the decision making need to be held responsible.


  19. The Opposite of Sex, Drugs, and Rock & Roll: Deborah's StoryRead the original story w/Photo

    May 6, 2015 | Psychology Today

    I'm delighted to welcome Elizabeth Saenger, my colleague at the Center for Environmental Therapeutics , for a new twist to our Chronotherapy blog. Elizabeth is a Harvard-educated psychologist who helps people help themselves live the way they want to, often with style and originality.


  20. Move for cheap drugsRead the original story

    May 6, 2015 | Yahoo!

    Some of the most commonly prescribed big-name drugs for cholesterol, depression and reflux will be up to $18.85 per script cheaper under a Federal Budget attack on medicine prices. _The West Australian _ can reveal that Health Minister Sussan Ley has included Australia's two biggest-selling prescription drugs - cholesterol-lowering atorvastatin and rosuvastatin, sold as Lipitor and Crestor - on a Federal Government hit list aimed at saving up to $2 billion over five years.